<DOC>
	<DOCNO>NCT01493778</DOCNO>
	<brief_summary>This trial conduct Asia , Europe North America . The purpose trial evaluate safety efficacy turoctocog alfa prevention treatment bleed previously untreated child haemophilia A .</brief_summary>
	<brief_title>Safety Efficacy Turoctocog Alfa Prevention Treatment Bleeds Previously Untreated Children With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Age 6 year Informed consent obtain trialrelated activity ( trialrelated activity procedure would perform normal management patient ) Male patient diagnose congenital severe haemophilia A ( FVIII level equal 1 % ) No prior use purified clot factor product ( previous exposure , equal less 5 ED blood component , e.g . cryoprecipitate , fresh frozen plasma , accept ) include commercially available NovoEight® /Novoeight® Known suspect allergy hamster protein intolerance trial product ( ) relate product Previous participation trial define withdrawal administration trial product Congenital acquire coagulation disorder haemophilia A Any history Factor VIII inhibitor Ongoing treatment plan treatment trial immunomodulatory agent ( e.g . intravenous immunoglobulin ( IVIG ) , routine systemic corticosteroid )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>